University White Paper on 340B Says Pharma and Hospitals Will Keep Testing 340B’s Bounds Until Congress Acts

Pharma and hospitals will keep testing the bounds of the 340B program until Congress steps in, a University of Southern California (USC) health policy research fellow predicts in a new white paper.

Drug manufacturers and hospitals “will likely continue to test the bounds” of the 340B program until Congress passes legislation addressing multiple concerns about it, a University of Southern California (USC) health policy research fellow says in a new white paper.

Read More »

Drug Manufacturers May Seek Orphan Designations to Avoid Paying 340B Discounts, HHS OIG Concludes

The 340B orphan drug exclusion incentivizes manufacturers to get orphan designations for drugs approved to treat common diseases or conditions, a new government report says.

The ban on 340B discounts on orphan drugs for rural and free-standing cancer hospitals may give drug companies a powerful incentive “to seek orphan designation for drugs approved to treat common diseases or conditions,” the U.S. Health and Human Services

Read More »

Managed Care Journal Article Gives 340B Hospitals Low Marks on Uncompensated Care

Researchers Sunita Desai (left) and J. Michael McWilliams, M.D., say they found no evidence that hospitals increased uncompensated care after entry into the 340B program any more than hospitals that never entered or had not yet entered the program.

Researchers who reported in 2018 that the 340B program leads to hospital-physician practice consolidation but probably not to better care or outcomes for low-income patients have released a new 340B study, this time on hospital provision of uncompensated care.

Read More »

340B Hospitals and Independent Oncologists Issue Dueling Reports on Drug Discount Program

340B hospitals and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.

Please Login or Become a Paid Subscriber to View this

Read More »

340B Hospitals Provide Almost $68 Billion Annually in Community Benefits, AHA Says

340B hospitals provided $67.9 billion in total community benefits in 2018, AHA reported yesterday.

Hospitals participating in the 340B program provided $67.9 billion in total benefits to their communities in 2018, the American Hospital Association (AHA) reported yesterday.

Please Login or Become a Paid Subscriber to View this Content

Read More »

FQHCs Say Patients Will Suffer if Telehealth Flexibilities Aren’t Extended

NACHC says millions of health center patients could lose access to care if Congress and the Biden administration fail to extend telehealth flexibilities granted during the COVID-19 pandemic.
Millions of community health center patients could lose access to care if Congress and the Biden administration fail to extend telehealth flexibilities granted during the COVID-19 pandemic, especially for audio-only telehealth, a new survey report warns.
Read More »

16 States Have Passed Laws Since 2019 Targeting PBMs’ 340B Payment Cuts

Drug reimbursement
A new tally of state laws and a new white paper are the latest signs of states' growing role in policing PBM efforts to ratchet down reimbursement for 340B-purchased drugs. | Shutterstock

Sixteen states have passed laws since 2019 addressing pharmacy benefit manager (PBM) discrimination against 340B covered entities, according to a draft summary of state action on the subject circulating among community health center advocates.

Meanwhile, two longtime 340B program policy

Read More »

Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say

A recent Supreme Court decision was a big win for 340B providers, K&L Gates partners (left to right) Don Walker, Leah D’Aurora Richardson, and Victoria Hamscho say in a new American Health Law Association paper.
A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.
Read More »

340B Sales Totaled $38 Billion Last Year, Industry Friendly Blog Reports

Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, says Adam Fein, writer of the Drug Channels blog.

Prescription drug sales through the 340B program totaled $38 billion in calendar year 2020, representing 7.2% of overall U.S. sales of $528 billion, Drug Channels blog reports.  Drug Channels is run by pharmaceutical manufacturer consultant Adam Fein, a leading critic

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

Sign up for news summaries and alerts from 340B Report